Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease

Table 1

Overview of key neutrophil related targets with association to chronic respiratory disease as potential therapeutic targets.

Target	Drug name	Selectivity	Company	Indication	Last reported status	Reference	Subjects	Duration (weeks)
CXCR2	AZD5069	CXCR2	Astrazeneca	Asthma	Phase 2	NCT01704495	640	26
				Bronchiectasis	Phase 2	NCT01255592	52	4
	Danirixin	CXCR2	Glaxosmithkline	COPD	Phase 2	NCT02130193	102	2
	Elubrixin	CXCR2	Glaxosmithkline	CF	Phase 2	NCT00903201	146	4
	Navarixin	CXCR1/2	Merck	Asthma	Phase 2	NCT00632502	37	4
				Asthma	Phase 2	NCT00688467	19	1.3
				COPD	Phase 2	NCT01006616	616	102
	QBM076	CXCR2	Novartis	COPD	Phase 2	NCT01972776	48	8
	SX-682	CXCR1/2	Syntrix	Asthma	Preclinical
DPP1	AZD7986		Astrazeneca	COPD	Phase 1	NCT02303574	237	4
	GSK2793660		Glaxosmithkline	Bronchiectasis	Phase 1	NCT02058407	33	2
MMP	AZD1236	9/12	Astrazeneca	COPD	Phase 2	NCT00758706	55	6
	AZD2551	12	Astrazeneca	COPD	Phase 1	NCT00860353	81	2
	AZD3342	8/9/12	Astrazeneca	COPD	Phase 1		49	2
	RBx 10017609	12	Glaxosmithkline & Ranbaxy	COPD	Phase 1
NE	AZD9668		Astrazeneca	Bronchiectasis	Phase 2	NCT00769119	38	4
				CF	Phase 2	NCT00757848	56	4
				COPD	Phase 2	NCT00949975	838	12
				COPD	Phase 2	NCT01023516	615	12
	BAY 85-8501		Bayer	Bronchiectasis	Phase 2	NCT01818544	94	4
	ONO-6818		Ono	COPD	Phase 2
PI3K	GSK2269557	δ	Glaxosmithkline	Asthma	Phase 2	NCT02567708	50	4
				COPD	Phase 2	NCT02294734	126	4
				COPD	Phase 2	NCT02522299	35	12
	GSK2292767	δ	Glaxosmithkline	Asthma	Phase 1	NCT03045887	44	2
	IPI-145	δ (/γ)	Infinity	Asthma	Phase 2	NCT01653756	46	2
	RV1729	δ (/γ)	RespiVert	Asthma	Phase 1	NCT01813084	63	2
				Asthma	Phase 1	NCT02140320	49	4
				COPD	Phase 1	NCT02140346	48	4
	RV6153	δ (/γ)	RespiVert	Asthma	Phase 1	NCT02517359	55	4